Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group Limited has announced that its bispecific fusion protein drug, JMT106, has received approval from the National Medical Products Administration of China to conduct clinical trials for advanced solid tumors. This approval, alongside a similar approval from the U.S. FDA, highlights the drug’s potential in treating various cancers, including hepatocellular carcinoma and ovarian cancer, and signifies a promising step in the company’s clinical development efforts.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.26 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a company incorporated in Hong Kong, operating in the pharmaceutical industry. It focuses on developing innovative drugs, with a market focus on treatments for various diseases, including cancer.
YTD Price Performance: 23.25%
Average Trading Volume: 145,397,173
Technical Sentiment Signal: Buy
Current Market Cap: HK$67.73B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.